article thumbnail

[UPCKat] Access to confidential information by parties and the public in the UPC

The IPKat

The UPCKat trying to keep confidential information confidential in the UPC As part of our UPCKat reporting on the latest UPC developments, the IPKat brings readers a roundup of how the UPC is treating confidentiality and third party access to court documents.

article thumbnail

Prior Art: The Patent Pitfall

Larson & Larson

Often, the reason that the patent office will cite for rejecting an application is the presence of prior art. This makes the term ‘prior art’ an important concept for inventors to understand. What is Prior Art? You may have heard the term ‘prior art’ before in the context of patents.

Art 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Aicon Art LLC v. Aicon Contemporary LLC:  A Reminder About the Importance of Knowing Who the Client Is

LexBlog IP

A September 27, 2023 decision by a Manhattan trial court, Aicon Art LLC v. 27, 2023), involving a dispute between two businesses located in the same art gallery, serves as a reminder to New York art market participants to take care to avoid attorney conflicts of interest. Aicon Contemporary LLC , No. 33340(U) (N.Y.

Art 40
article thumbnail

Weakness of SELF Magazine's Mark Leads to TTAB Dismissal of Opposition to THE SELF PUBLICATION for Art and Literature Presentations

The TTABlog

As to the goods and services, the opposer application is limited to presentation of works of literature and art for cultural and educational purposes. The Board found this evidence to be substantial, but it concerned only recent years and lacked industry context, and the revenue figures were not limited to the United States.

Art 70
article thumbnail

Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry

Bio Law Blog

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

article thumbnail

Trade Secrets in Intellectual Property Rights (IPRs)

Kashishipr

In simple terms, trade secrets are Intellectual Property Rights (IPRs) granted on confidential or sensitive info, which may be licensed or sold. Generally, any confidential piece of business info that provides a competitive edge to a company or firm and isn’t known to others may be safeguarded as a trade secret.

article thumbnail

Best Practices for Intellectual Property Management in Small to Medium Enterprises (SMEs)

Intepat

Intellectual property transforms knowledge into an economic result by interacting with legal and economic forces in the market. Intellectual Property is revealed by the gap between a company’s book value and market value. These intellectual outputs are seen across industries, including creative and cultural sectors.